2023
DOI: 10.1038/s41598-023-32046-0
|View full text |Cite
|
Sign up to set email alerts
|

Association between asymmetric dimethylarginine and sarcopenia in community-dwelling older women

Abstract: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelium nitric oxide synthesis and causes endothelial dysfunction that may be related to sarcopenia. However, the association between ADMA and sarcopenia has not been studied. We evaluated the correlations between plasma ADMA levels and sarcopenia in community-dwelling older women. In total, 144 community-dwelling older women participated in this study. Plasma ADMA levels were measured using a competitive enzyme-linked immunosorbent assay. Sk… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 29 publications
0
1
0
Order By: Relevance
“…Alternatively, other bio evidence can be used to indirectly estimate lower grip strength and muscle power. For instance, an increment in plasma asymmetric dimethylarginine (ADMA) level can be measured and is significantly associated with low grip strength and sarcopenia [ 14 ]. In [ 15 ], serum proteomics analysis was used to identify novel biomarkers for the diagnosis of sarcopenia, which found a total of 114 deferentially expressed proteins (DEPs) between the patients and healthy older adults, including 48 upregulated proteins and 66 downregulated proteins, and identified cholesterol ester transfer protein and Apolipoprotein A2 as potential biomarkers that are related to low muscle power.…”
Section: Physical Performance Test For Sarcopeniamentioning
confidence: 99%
“…Alternatively, other bio evidence can be used to indirectly estimate lower grip strength and muscle power. For instance, an increment in plasma asymmetric dimethylarginine (ADMA) level can be measured and is significantly associated with low grip strength and sarcopenia [ 14 ]. In [ 15 ], serum proteomics analysis was used to identify novel biomarkers for the diagnosis of sarcopenia, which found a total of 114 deferentially expressed proteins (DEPs) between the patients and healthy older adults, including 48 upregulated proteins and 66 downregulated proteins, and identified cholesterol ester transfer protein and Apolipoprotein A2 as potential biomarkers that are related to low muscle power.…”
Section: Physical Performance Test For Sarcopeniamentioning
confidence: 99%